The trajectory of companies tied to iconic drugs like Viagra presents a challenging investment picture. While the initial rise of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the patent expiration in key regions has introduced substantial risk . Investors are now facing the impact of generic competition , r